James E Galvin

James E Galvin is a neuroscientist at Florida Atlantic University.[12]He specializes in clinical biomedical science and clinical research.[34]

Galvin is a professor of clinical biomedical science and associate dean for clinical research in the Charles E. Schmidt College of Medicine at Florida Atlantic University, and has a joint appointment as a professor in FAU’s Christine E. Lynn College of Nursing.[5]Previously, he held faculty positions at Washington University in St. Louis and at Hahnemann University in Philadelphia.[5]He also is one of the leading international experts on “Lewy Body disease” where patients simultaneously experience losses in cognitive function, mobility and behavior.[6]He also has developed the Quick Dementia Rating System, which uses an evidence-based methodology to validly and reliably differentiate individuals with and without dementia.[7]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

James E Galvin on Wikipedia

To update Wikipedia with this information, visit the page for the subject above.

Florida Atlantic University


  • 1


  • 302


  • 32



Study captures economic burden of frontotemporal degeneration in the United States

The study, published in Neurology ®, the medical journal of the American Academy of Neurology, reveals that costs associated with FTD are twice that of Alzheimer's disease . The researchers also found that costs for FTD were greater in the U.S. than in studies originating in other countries and the implications for patients and their caregivers are dire. "Frontotemporal degeneration is associated with substantial direct and indirect costs, diminished quality of life, and increased caregiver burden," said James E. Galvin, M.D., M.P.H., lead author, associate dean for clinical research in FAU's Charles E. Schmidt College of Medicine, and a leading international expert on AD, Lewy Body Dementia , and FTD. For the study and to quantify the socioeconomic burden of this disease, the researchers conducted a web-based survey to characterize the patient and caregiver experience with FTD-related resource use, health-related quality of life, and per-patient annual costs. At the time of the survey, 45 percent of caregivers still worked, while 37 percent were no longer employed after the patient's FTD diagnosis.[8]


Event Date